← Leaderboards
Lynne I. Wagner
Northwestern University At Chicago
$72,851,464
Attributed
$188,754,734
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $28.1M · FY2013–25$50M$37.5M$25M$12.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$188,754,734 · 4
By mechanism
UG1$183,616,051 · 1
U01$3,407,413 · 1
R01$1,366,668 · 1
R21$364,602 · 1
Top collaborators
- Mitchell D Schnall20 shared
- Peter J O'Dwyer15 shared
- Robert J Gray6 shared
- Ruth C Carlos1 shared
Most similar at Northwestern University At Chicago
Same institution · by research overlap
- Melissa A. Simon$40,197,785
- Joseph M Feinglass$775
- William J Catalona$3,906,973
- Simon M. Lin$2,428,632
- Borko Jovanovic$2,063,904
Others in their field
Top investigators on “Eastern Cooperative Oncology Group”
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$183,301,859
- Peter J O'Dwyer · University Of Pennsylvania$127,068,301
- Robert J Gray · Dana-Farber Cancer Institute$68,097,614
- Mitchell D Schnall · University Of Pennsylvania$59,929,052
- Jean Macdonald · Dana-Farber Cancer Inst$26,990,229
- Gregory A Masters · Christiana Care Health Services, Inc.$18,268,728
Research focus
Eastern Cooperative Oncology GroupAmerican College Of Radiology Imaging NetworkBaseProviderSymptomsMonitorCancer TherapyCollaborationsPatient Outcomes AssessmentsClinical TrialsMalignant NeoplasmsReportingProgramsAdvocateTherapeutic TrialsCommunity Clinical Oncology ProgramCaringCancer SurvivorshipDiagnosisInnovationCommunitiesMeasurementAnticancer ResearchEnsure
Grant awards (31)
ECOG-ACRIN NCORP Research Base$17,746,015
UG1 · FY2025 · CA · contact PI
Randomized controlled trial of FoRtitude: Targeted eHealth intervention to reduce fear of recurrence among breast cancer survivors in community oncology settings$657,618
R01 · FY2025 · CA · contact PI
ECOG-ACRIN NCORP Research Base$79,202
UG1 · FY2025 · CA · contact PI
ECOG-ACRIN NCORP Research Base$18,695,221
UG1 · FY2024 · CA · contact PI
Randomized controlled trial of FoRtitude: Targeted eHealth intervention to reduce fear of recurrence among breast cancer survivors in community oncology settings$709,050
R01 · FY2024 · CA · contact PI
ECOG-ACRIN NCORP Research Base - TMIST$18,423,048
UG1 · FY2023 · CA · contact PI
ECOG-ACRIN NCORP Research Base$5,154,867
UG1 · FY2023 · CA · contact PI
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)$350,000
U01 · FY2023 · CA
ECOG-ACRIN NCORP Research Base$26,214,534
UG1 · FY2022 · CA · contact PI
ECOG-ACRIN NCORP Research Base$945,901
UG1 · FY2022 · CA · contact PI
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)$614,234
U01 · FY2022 · CA
ECOG-ACRIN NCORP Research Base$322,207
UG1 · FY2022 · CA · contact PI
ECOG-ACRIN NCORP Research Base$7,343,401
UG1 · FY2021 · CA · contact PI
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)$589,450
U01 · FY2021 · CA
ECOG-ACRIN NCORP Research Base$388,169
UG1 · FY2021 · CA · contact PI
ECOG-ACRIN NCORP Research Base$385,270
UG1 · FY2021 · CA · contact PI
ECOG-ACRIN NCORP Research Base$17,691,650
UG1 · FY2020 · CA · contact PI
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)$618,498
U01 · FY2020 · CA
ECOG-ACRIN NCORP Research Base$392,177
UG1 · FY2020 · CA · contact PI
ECOG-ACRIN NCORP Research Base$123,705
UG1 · FY2020 · CA · contact PI
COVID-19 RELated Barriers to Trial Participation Equity (CO-RELaTE)$118,727
UG1 · FY2020 · CA · contact PI
ECOG-ACRIN NCORP Research Base$20,443,862
UG1 · FY2019 · CA · contact PI
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)$533,791
U01 · FY2019 · CA
ECOG-ACRIN NCORP Research Base$24,264,307
UG1 · FY2018 · CA · contact PI
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)$701,440
U01 · FY2018 · CA
ECOG-ACRIN NCORP Research Base$12,699,758
UG1 · FY2017 · CA · contact PI
ECOG-ACRIN NCORP Research Base$3,547,244
UG1 · FY2016 · CA · contact PI
ECOG-ACRIN NCORP Research Base$4,227,002
UG1 · FY2015 · CA · contact PI
ECOG-ACRIN NCORP Research Base$4,409,784
UG1 · FY2014 · CA · contact PI
Targeted eHealth intervention to reduce fear of recurrence among cancer survivors$162,979
R21 · FY2014 · CA · contact PI
Targeted eHealth intervention to reduce fear of recurrence among cancer survivors$201,623
R21 · FY2013 · CA · contact PI